RiverVest Venture Partners focuses exclusively on innovations in life sciences, a field in which their team has significant research, clinical, operational and investment expertise. The team's deep domain experience allows them to identify promising investment opportunities, particularly in biopharmaceuticals and medical devices. They provide practical advice and strategic leadership to help entrepreneurs drive early-stage companies forward. RiverVest founds and actively incubates life science companies, including through its Archer Seed Fund. The Firm also invests in select later-stage opportunities to diversify risk and maximize portfolio returns. In every case, it takes a hands-on investment approach, preferring to be represented on the boards of their portfolio companies.
Amplyx Pharmaceuticals, Inc. is a preclinical stage company focusing on the development of small molecule drugs.
Now Avalyn Pharma, a biopharmaceutical company developing therapies to treat idiopathic pulmonary fibrosis and other respiratory diseases
A biopharmaceutical company focused on developing treatments for inner and middle ear diseases
OncoResponse is a company providing cancer research into immunotherapies and the newest technologies for oncologists.
A company that develops therapeutic antibodies to treat diseases and allergies
Mirum Pharmaceuticals is a Menlo Park, California-based company.
InterVene is a South San Francisco, California-based company.